| Literature DB >> 31908703 |
Bartłomiej Łasocha1, Paweł Brzegowy2, Agnieszka Słowik3, Paweł Latacz3, Roman Pułyk3, Tadeusz J Popiela2.
Abstract
INTRODUCTION: Reperfusion therapy for acute ischaemic stroke used within a time window of 6 h following symptom onset, although currently the treatment of choice, is characterised by certain limitations and carries certain risks. AIM: To assess the potential for predicting the risks and limitations of reperfusion therapy by means of advanced neuroimaging.Entities:
Keywords: computed tomography; mechanical thrombectomy; stroke
Year: 2019 PMID: 31908703 PMCID: PMC6939209 DOI: 10.5114/wiitm.2019.84761
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Clinical characteristics of the study group (n = 85)
| Parameter | Result |
|---|---|
| Age | 69 (58–77) |
| Sex (female) | 39 (46%) |
| Occlusion site: | |
| M1 | 52 (61%) |
| M2 | 18 (21%) |
| ICA | 4 (5%) |
| Tandem | 11 (13%) |
| Diabetes | 24 (28%) |
| Atrial fibrillation | 37 (44%) |
| Hypertension | 66 (78%) |
| Ischaemic heart disease | 30 (35%) |
| NIHSS at admission | 16 (12–19) |
| Intravenous thrombolysis | 66 (78%) |
M1 – M1 segment of the middle cerebral artery from its origin to bifurcation/trifurcation, M2 – M2 segment of the middle cerebral artery, also known as the insular segment, ICA – internal carotid artery, NIHSS – National Institute of Health Stroke Scale; clinical measure of stroke/neurologic deficit; the scale includes values in the range 0‒42; an NIHSS score > 21 is assumed to represent a severe stroke, TANDEM – internal carotid artery and middle cerebral artery occlusion in the entire segment with or without visible blood flow in between (through the ophthalmic artery or either communicating artery).
Group comparison of good vs. poor clinical outcomes
| Variable | Good clinical outcome MRS ≤ 2, | Poor clinical outcome MRS > 2, | |
|---|---|---|---|
| NIHSS, median (IQR) | 14.5 (11–18) | 17.5 (14–19) | 0.029 |
| Age, median (IQR) | 67 (51.75–73.5) | 72 (66.5–80) | 0.004 |
| Recanalisation (TICI 2b or 3; | 41 (82%) | 14 (40%) | 0.004 |
| Time to treatment, median (IQR) [min] | 209 (165.5–260) | 238 (172.25–297) | 0.228 |
| Ischaemic heart disease, | 15 (30%) | 15 (42.86%) | 0.317 |
| Myocardial infarction, | 4 (8%) | 7 (20%) | 0.353 |
| Sex (female), | 21 (42%) | 18 (51.43%) | 0.463 |
| Atrial fibrillation, | 20 (40%) | 17 (48.57%) | 0.508 |
| Diabetes, | 13 (26%) | 11 (32.43%) | 0.673 |
| BMI, median (IQR) | 27.68 (24.78–31.22) | 28.68 (25.48–30.12) | 0.699 |
| Hypertension, | 38 (76%) | 28 (80%) | 0.759 |
| Intravenous thrombolysis, | 39 (78%) | 27 (77.14%) | 0.947 |
Figure 1Proportion of good and poor clinical outcomes in SMCTS groups. Box and whiskers chart in SMCTS groups
Haemorrhages in SMCTS 1 and 2 patients
| Factor | Insignificant bleeding or none | Clinically significant haemorrhage | |
|---|---|---|---|
| Reperfusion, | 20 (77%) | 0 | 0.008 |
| Atrial fibrillation, | 7 (27%) | 1 (33%) | 0.853 |
| Age, median (IQR) | 59 (50–78) | 60 (59–66) | 0.693 |
| NIHSS, median (IQR) | 15 (13–20) | 18 (15–19) | 0.857 |
| Intravenous thrombolysis, | 22 (85%) | 2 (67%) | 0.477 |
| Collaterals, | 15 (58%) | 2 (67%) | 0.801 |
| Time to treatment, median (IQR) | 224 (176–299) | 240 (233–278) | 0.333 |
| Sex (female), | 11 (42%) | 0 | 0.173 |